​The current focus areas for the Meyerson laboratory include lung cancer genomics and biology, the non-coding cancer genome, the cancer microbiome, and genome-inspired cancer drug discovery. Current projects in the lab include:

Germline influence on somatic mutation in the EGFR gene in lung adenocarcinoma.

Mutational analysis of a large lung cancer patient cohort, the ALCHEMIST trial.

Structure-function analysis of EGFR.

Sensitizing lung cancers to EGFR inhibitors.

Role of inflammatory response and RNA metabolism in lung cancer cell survival

Function of the CMTR2 tumor suppressor gene.

Function of the NKX2-1 lineage survival gene in lung adenocarcinoma.

Something on microbiome biology

---

Lung cancer is the leading cause of cancer death in the United States and worldwide. The Meyerson laboratory has focused on understanding lung cancer biology by interrogating the lung cancer genome. Over the past decades, Dr. Meyerson and colleagues have discovered genes and gene alterations important in human cancer, including 

• Human cyclin-dependent kinase family including CDK2 and CDK6
• The human telomerase catalytic subunit gene TERT
• Somatic mutations in lung cancer in EGFR, U2AF1, RBM10, HLA genes and others
• Copy number alterations including lineage amplifications of SOX2 and NKX2-1 in lung cancers.
• The biology and translational potential of cancer aneuploidy.